Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Long-Term Follow-Up Study of Participants Exposed to REACT
Sponsor: Prokidney
Summary
The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).
Official title: A Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy From Studies RMCL-002, REGEN-003, REGEN-004
Key Details
Gender
All
Age Range
30 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
80
Start Date
2023-12-11
Completion Date
2028-03
Last Updated
2025-05-28
Healthy Volunteers
No
Interventions
Renal Autologous Cell Therapy (REACT)
No interventions in this trial
Locations (1)
Boise Kidney & Hypertension Institute
Meridian, Idaho, United States